Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi has struck a $9.5 billion deal to buy Blueprint Medicines for an approved rare disease drug and an early-stage immunology pipeline. Leerink analyst Andy…
Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key…
The companies in June agreed to a $9.5 billion acquisition deal, giving Sanofi the FDA-approved systemic mastocytosis drug Ayvakit and a pipeline of…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Sanofi agreed to acquire Blueprint for $129.00/share cash ($9.1B equity) plus CVRs of $2 (BLU-808 clinical milestone) and $4 (BLU-808 regulatory milestone), total up to $9.5B. Adds Ayvakit, the only approved therapy for advanced and indolent systemic mastocytosis, plus early-stage immunology pipeline. Completed July 18, 2025.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Blueprint Medicines Corporation (this deal) | 2025 | $9.5B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2025 deals · Sanofi SA deals · Immunology deals